Xevudy (sotrovimab), made by pharmaceutical giant GlaxoSmithKline (GSK), has been found to cut hospital admission and death by 79% in those at risk.

A new clinical study is being launched to see whether two Covid-19 antibody treatments made by different pharmaceutical companies can be combined to improve patient outcomes.